Scientific Program

October 16th, 2019
08.00 – 09.40 Oral presentations
  Chairs: Hacı Mehmet Turk, Ilhan Gecit
 
09.40 – 10.00 Opening remarks
  M. Ihsan Karaman – President of Congress
Gerasimos Alivizatos – President of Hellenic Urological Association
Selami Albayrak – President of Euroasian Uro-oncological Association
 
10.00 – 11.30 Session 1- Mechanism and biology – Diagnosis and treatment of urothelial Cancer
  Chairs: Yasar Ozgok, Gerasimos Alivizatos
10.00 – 10.15 Molecular pathways in urothelial cancer – Dilek Telci
10.15 – 10.30 Genomic philosophy and biomarkers for treatment selection in urothelial cancer – Peter Black
10.30 – 10.40 Discussion
10.40 – 11.20

BCG refractory diseases

  • Mechanism of resistance to BCG – Oktay Akca
  • The clinical impacts of pathological variants in BCG response – Ioannis Varkarakis
  • Predictive markers of BCG response – Murat Bozlu
  • Immunotherapy in non-muscle invasive bladder cancer – Ozcan Yildiz
11.20 – 11.30 Discussion
 
11.30 – 11.50 Coffee Break
 
11.50 – 12.55 Session 2- Diagnosis and treatment of urothelial cancer-1
  Chairs: A. Yaser Muslumanoglu, Nikolaos Ferakis
11.50 – 12.05 Imaging modalities in staging bladder cancer prior to radical cystectomy – Nathan Lawrentschuk
12.05 – 12.25

Debate: The optimal local treatment for muscle invasive bladder cancer

  • Trimodality treatment – Hale Çağlar
  • Radical cystectomy – Oner Sanli
12.25 – 12.35 Discussion
12.35 – 12.50 Robotic-assisted radical cystectomy versus open radical cystectomy – Nathan Lawrentschuk
12.50 – 13.05

Biomarker-based approach to neoadjuvant chemotherapy for muscle invasive bladder cancer – Peter Black

 
13.05 – 13.45 Lunch
 
13.45 – 14.30 Challenging cases in bladder cancer
  Case Panel Discussion
Moderator: Tarik Esen
Panelists: Nathan Lawrentschuk, Altug Tuncel, Ozgur Ozyilkan, Taner Korkmaz, Hale Caglar
 
14.30 – 15.45 Session 3 – Diagnosis and treatment of urothelial cancer – 2
  Chairs: Eyup Gumus, Abdurrahim Imamoglu, Ozgur Ozyilkan
14.30 – 14.45 What is the ideal time to start immunotherapy in metastatic muscle invasive bladder cancer? – Mehmet Artac
14.45 – 15.15

How can we improve the functional outcomes in radical cystectomy?

  • (Is still) Prostate sparing approach – Yilmaz Aslan
  • Robotic nerve sparing radical cystectomy – Why do I recommend? – Ali Fuat Atmaca
  • Open nerve sparing radical cystectomy – Ozdal Dillioglugil
15.15 – 15.25 Discussion
15.25 – 15.45

Debate: Is there a role of metastasectomy in urothelial cancer?

  • Yes – Selcuk Şahin
  • No – Fatih Kose
 
15.45 – 16.05 Coffee Break
 
16.05 – 17.05 Best posters in EUA 2019
  Chairs: Mahmut Gumus, Ali Ihsan Tasci
 
17.05 – 18.00 B2B Session in EUA 2019
  Chairs: Basak Oven, Archil Chkhotua
17.05 – 17.25 Variants and new entities of bladder cancer – Gozde Kir
17.25 – 18.00

Hot topics and clinical reflections

  • Bladder cancer – Emrah Yuruk
  • Metastatic prostate cancer – Fatih Selcuk Biricik
  • Renal cancer – Volkan Tugcu

 

October 17th, 2019
07.15 – 16.35 World Urological Oncology Federation Symposium

 

Chair: Laurence Klotz, Canada

07:15 – 07:45

Meet and Greet International Colleagues – Coffee served. For WUOF attendees only.

07:45 – 07:50  

Framing of Theme – Laurence Klotz, Canada

   
07:50 – 09:55 Session One. Early Detection and Treatment of Localized Prostate Cancer

07:55 – 08:10

A Biostatistician’s View of Prostate Cancer Screening

08:10 – 08:25

Early Detection of Prostate Cancer in a Resource Constrained Environment

08:25 – 08:40

The Impact of Positive Surgical Margins, Biochemical Recurrence or PSA Persistence on Oncological Outcomes after Radical Prostatectomy

08:40 – 08:55

Retzius Sparing RP: Is it Beneficial?

08:55 – 09:05

nmCRPC – Does It Exist?

09:05 – 09:10

Discussion

09:10 – 09:25

Strengths and Limitations of PSMA PET

09:25 – 09:45

Debate: Does RP Have a Role in the Management of Oligomets?

09:45 – 09:55

Discussion

   
09:55 – 11:10 Session Two. Prostate Cancer Management Options

10:00 – 10:15

Salvage Lymphadenectomy in the PSMA Era: Where to Draw the Line?

10:15 – 10:30

The Phenomenology and Epistemology of the Androgen Receptor

10:30 – 10:45

Timing of ADT in the Era of Stampede and Latitude

10:45 – 11:00

Chemotherapy and ARATs vs Metastases-Directed Therapy for mHSPC

11:00 – 11:10 

Discussion

   
11:10 – 12:40 Session Three. Renal Cancer

11:15 – 11:30 

Cytoreductive Nephrectomy — Has it Had Its Day?

11:30 – 11:45

Management of RCC Caval Thrombus in 2019

11:45 – 12:00

Adjuvant Therapy for High Risk RCC: Current Status

12:00 – 12:15

Active Surveillance for Small Renal Masses: Where to Draw the Line?

12:15 – 12:25

Discussion

12:25 – 12:40

SPECIAL LECTURE: POWER POINT 101. Fumble at the Goal Line: How Presenters Hijack Attention and Lose Their Audience

   
12:40 – 13:05 Working Lunch
Meal voucher required. Complimentary meal to all seated participants attending Session Four Working Lunch.
   
13.05 – 13:25 Session Four | The Internationals

13:05 – 13:10

Introduction
Laurence Klotz, Canada
The 2019 ICUD: Biomarkers in Urologic Oncology

13:10 – 13:20

History and Impact of ICUDs

13:20 – 13:25

Current WUOF-SIU-ICUD

   
13:25 – 15:15 Session Five. Town Hall – Innovation and the Molecular Revolution

13:30 – 13:45

Special Guest Lecture: How to Ensure Innovation in Urologic Oncology?

13:45 – 13:50

Discussion

13:50 – 14:50

Panel. How to Ensure Innovation: Urologist & Industry Perspectives

14:50 – 15:10

Open Discussion

   
15:15 – 15:35 Session Six. Germ Cell Tumours

15:20 – 15:35

Update on the Management of Complex Germ Cell Tumors

   
15:35 – 16:35  Session Seven. Advanced Prostate Cancer Treatment Options

15:40 – 15:55

Role of Estrogen in the Management of Prostate Cancer

15:55 – 16:10

Theranostic Application of PSMA-Labeled Lutetium-177

16:10 – 16:25

Novel therapies for CRPC

16:25 – 16:35

Discussion

16:35 – 16:35

Adjourn

 

October 18th, 2019
08.00 – 09.30 Session 4 – Metastatic prostate cancer
  Chairs: Atif Akdas, Theodoros Kalogeropoulos
08.00 – 08.15 Characteristics and Structural Variations of Genome in Metastatic Prostate Cancer – Christopher P. Evans
08.15 – 08.30 The Role of PET-CT in Metastatic Prostate Cancer – What Urologists think? – Konstantinos Stravodimos
08.30 – 08.55 Improving outcome and reducing morbidity with ADT – Laurence Klotz
08.55 – 09.15 Current Status of Theranostics in Prostate Cancer – Meltem Caglar Tuncali
09.15 – 09.30 Role of immunotherapy in Mcrpc: A new hope – Timucin Cil
 
09.30 – 10.10 Session 5 – Oligometastatic prostate cancer
  Chairs: Selami Albayrak, Jean de la Rosette, Bülent Orhan
09.30 – 10.00
  • Urologists’ perspective – Faruk Ozcan
  • Oncologists’ perspective – Fuat Demirelli
  • Radiation oncologists’ perspective – Hale Basak Caglar
10.00 – 10.10 Discussion
 
10.10 – 10.30 Coffee Break
 
10.30 – 11.30 Challenging cases in metastatic prostate cancer – Case Panel Discussion
  Moderators: Laurence Klotz, Damien Bolton
Panelists: Bulent Akduman, Fatih Atug, Metin Ozkan, Cagatay Arslan, Meltem Caglar Tuncali
 
11.30 – 12.10 Session 6 – Renal cancer: Locally advanced and metastatic
  Chairs: Turhan Caskurlu, Salim Basol Tekin
11.30 – 11.50 Fraility in RCC – Selcuk Guven
11.50 – 12.10

Situation after CARMENA

  • Urologists’ perspective – Pilar Laguna
  • Onclogists’ perspective – Umut Kefeli
 
12.10 – 13.00 Challenging cases in RCC
  Moderator: Pilar Laguna
Panelists: Mehmet Kucukoner, Yiğit Akin, Omer Levent Tuncay, Faysal Dane